Inspra

Eplerenone, the active ingredient in Inspra, is a mineralocorticoid receptor antagonist presented as an oral tablet for oral use. It is used to treat hypertension and heart failure in adult patients. By selectively blocking aldosterone receptors, it helps lower blood pressure and reduces cardiac remodeling.

GNH USA supplies Inspra as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company ensures quality manufacturing, regulatory compliance, and reliable distribution across global markets.

Eplerenone is indicated for conditions involving the renin‑angiotensin‑aldosterone system, primarily hypertension and heart failure.

- Hypertension: helps lower elevated blood pressure by antagonizing aldosterone‑mediated sodium retention. - Heart failure with reduced ejection fraction: improves survival and reduces hospitalizations by decreasing cardiac remodeling. - Post‑myocardial infarction heart failure: reduces risk of cardiovascular death and heart‑failure related events after an MI.

Eplerenone may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Hyperkalemia: elevated blood potassium levels, potentially causing muscle weakness. - Dizziness or light‑headedness: especially upon standing. - Headache: mild to moderate intensity. - Fatigue: general feeling of tiredness. - Gastrointestinal discomfort: nausea, abdominal pain or diarrhea.

Serious or Rare Side Effects: - Severe hyperkalemia: can lead to cardiac arrhythmias. - Acute kidney injury: sudden decline in renal function. - Angioedema: swelling of face, lips, tongue or throat. - Hepatic injury: elevated liver enzymes or hepatitis. - Anaphylactic reaction: rare severe allergic response.

When prescribing or dispensing eplerenone, several safety considerations should be observed.

- Monitor potassium levels: check serum K⁺ regularly, especially after dose changes. - Assess renal function: evaluate creatinine and eGFR before initiation and during therapy. - Use caution in elderly: increased sensitivity to blood pressure changes. - Avoid in patients with existing hyperkalemia: contraindicated when serum K⁺ >5.0 mmol/L. - Review concomitant medications: adjust doses of drugs that affect potassium or renal function. - Store at room temperature: keep in original container, protect from moisture and direct sunlight.

Eplerenone can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Potassium‑sparing diuretics (e.g., spironolactone, amiloride): may cause dangerous hyperkalemia. - ACE inhibitors or ARBs: additive effect on potassium and renal function. - NSAIDs (e.g., ibuprofen, naproxen): can impair renal clearance and increase potassium. - Cyclosporine: raises eplerenone plasma levels, heightening toxicity risk.

Moderate Interactions (Monitor Closely): - Digoxin: increased risk of digoxin toxicity with elevated potassium. - Lithium: reduced lithium clearance, may lead to toxicity. - Certain antibiotics (e.g., trimethoprim‑sulfamethoxazole): can raise potassium levels. - Antifungal agents (e.g., fluconazole): may increase eplerenone concentrations.